March 10, 2026
The sarcoma and follicular lymphoma drug tazemetostat (Tazverik) is being voluntarily pulled from the US and all other markets due to the risk of secondary hematologic […]
March 10, 2026
Patients aged 12 years and older with astrocytoma or oligodendroglioma will be able to access vorasidenib on NHS Scotland after the Scottish Medicines Consortium (SMC) accepted […]
March 10, 2026
Women with breast cancer who use alternative therapies instead of conventional medical treatments have a higher risk for death over 5 years — even if they […]
March 9, 2026
TOPLINE: In an interim analysis of a phase 2/3 study, neoadjuvant therapy with gemcitabine–oxaliplatin, lenvatinib, and toripalimab (GOLP regimen) more than doubled the median event-free survival […]
March 9, 2026
TOPLINE: In a phase 2 study, neoadjuvant sacituzumab govitecan plus pembrolizumab achieved a promising clinical complete response rate and had a favourable safety profile in patients […]
March 9, 2026
TOPLINE: State Medicaid expansion was associated with a lower risk for death within 2 years and a higher likelihood of surgical resection among adults with pancreatic […]
March 6, 2026
Adding MRI to routine biennial mammography screening for women aged 40 years or older with extremely dense breasts and increased breast cancer risk showed promise for […]
March 6, 2026
The FDA has approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for the treatment of certain adult […]
March 6, 2026
False cancer treatment claims continue to circulate widely on social media. Although often shared by well meaning friends, family members, and caregivers seeking to offer hope […]